Dizal Secures Breakthrough Therapy Designation for Sunvozertinib in Advanced NSCLC Treatment

Dizal (, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that th...

October 14, 2024 | Monday | News
Burning Rock and Dizal Announce First NGS-Based Lung Cancer Diagnostic Approval by China’s NMPA

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision onco...

October 11, 2024 | Friday | News
Basilea Pharmaceutica Secures $1.25 Million Milestone Payment Following Strong Sales of Cresemba® in Asia Pacific and China

Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and ...

October 10, 2024 | Thursday | News
NovaCina Expands Perth Facility with Advanced SA25 GMP Filling Line to Enhance Global CDMO Services

NovaCina, a global contract development and manufacturing organization (CDMO), has today announced the expansion of its facility in Perth, Australia with...

October 08, 2024 | Tuesday | News
Regor Sells Next-Gen CDK Inhibitors to Genentech in $850 Million Deal

Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor ...

October 07, 2024 | Monday | News
Kailera Therapeutics Launches with Ambitious Plans for GLP-1 Drugs Targeting Obesity and Metabolic Conditions

In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...

October 02, 2024 | Wednesday | News
IASO Biotherapeutics and Chinese Experts Explore Collaboration with Brazil on Cutting-Edge Cancer Therapies

On the eve of the International Myeloma Society (IMS) Annual Meeting, Dr. Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along ...

September 30, 2024 | Monday | News
European Commission Approves Junshi Biosciences' Toripalimab for Two Key Cancer Indications

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...

September 25, 2024 | Wednesday | News
EMA's CHMP Recommends Approval of Intas Pharmaceuticals' HETRONIFLY® (Serplulimab) for Extensive-Stage Small Cell Lung Cancer

Intas Pharmaceuticals announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive op...

September 23, 2024 | Monday | News
Nicox’s ZERVIATE® Approved for Ocular Itching in China, Set to Launch with Ocumension Therapeutics

Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China wil...

September 18, 2024 | Wednesday | News
Nuance Pharma Expands Bentrio® Nasal Spray Reach Across East and South East Asia

Altamira Therapeutics announces the extension of its exclusive license with Nuance Pharma to cover Singapore, Malaysia, Thailand, Philippines, Indonesia,...

September 17, 2024 | Tuesday | News
PolTREG Secures Chinese Patent for Intrathecal Administration of MS Therapy, Set to Launch Phase 2 Trials

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal...

September 16, 2024 | Monday | News
FDA Issues Warning Letters to Two Chinese Testing Labs Over Data Integrity and Animal Care Violations

Firms Provided Third-Party, Nonclinical Premarket Testing; Agency Review Ongoing U.S. Food and Drug Administration issued warni...

September 12, 2024 | Thursday | News
Oneness Biotech and Microbio's Pan-COVID Drug SNS812 Achieves Key Phase 2 Trial Success, Showing Broad-Spectrum Efficacy

Oneness Biotech and Microbio (Shanghai) announced that the pan-COVID New Drug, SNS812, co-developed by both companies achieves statistical significance wit...

September 11, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close